![]() 990,553,270 visitors served. |
|
![]() Dictionary/ thesaurus | ![]() Medical dictionary | ![]() Legal dictionary | ![]() Financial dictionary | ![]() Acronyms | ![]() Idioms | ![]() Encyclopedia | ![]() Wikipedia encyclopedia | ? |
monoclonal antibody |
Also found in: Dictionary/thesaurus, Medical, Acronyms, Wikipedia, Hutchinson | 0.02 sec. |
|
monoclonal antibody, an antibody that is mass produced in the laboratory from a single clone and that recognizes only one antigen. Monoclonal antibodies are typically made by fusing a normally short-lived, antibody-producing B cell (see immunity immunity, ability of an organism to resist disease by identifying and destroying foreign substances or organisms. Although all animals have some immune capabilities, little is known about nonmammalian immunity. ..... Click the link for more information. ) to a fast-growing cell, such as a cancer cell (sometimes referred to as an "immortal" cell). The resulting hybrid cell, or hybridoma, multiplies rapidly, creating a clone that produces large quantities of the antibody. Monoclonal antibodies engendered much excitement in the medical world and in the financial world in the 1980s, especially as potential cures for cancer. They have been used in laboratory research and in medical tests since the mid-1970s, but their effectiveness in disease treatment has been limited. By the mid-1990s, however, some of the technical problems had been overcome. Experimental cancer therapies have used drugs, radioactive materials, or immune killer cells attached to monoclonal antibodies that, when injected into patients, home in on antigens that grow only on the surface of cancer cells. |
|
? Mentioned in | ? References in periodicals archive | ||
|---|---|---|---|
| The partners have produced a monoclonal antibody with a high level of neutralization activity against HIV as part of a therapeutic drug for AIDS. A monoclonal antibody is a particle that latches on to a specified protein, for example, a receptor on the surface of certain immune cells. The companies plan to combine Medarex's fully human monoclonal antibody development technology and ZymoGenetics' expertise in the field of genomics and protein therapeutics to create antibodies to multiple disease targets identified by ZymoGenetics. |
| Free Tools: |
For surfers:
Browser extension |
Word of the Day |
Help
For webmasters: Free content NEW! | Linking | Lookup box | Double-click lookup | Partner with us |
|
|---|